Serum circRNA (Circ)_0051386 assists in the diagnosis of acute ST-segment elevation myocardial infarction and prediction of the occurrence of major adverse cardiovascular events after percutaneous coronary intervention

Abstract

Background

This study aimed to uncover the diagnostic value of circRNA (Circ)_0051386 in acute ST-segment elevation myocardial infarction (STEMI) and its predictive value for the occurrence of adverse major adverse cardiovascular events (MACEs).

Methods

This study included 166 patients with STEMI and 83 health donors. The expression levels of serum Circ_0051386 in these participants were quantified using real-time quantitative polymerase chain reaction (RT-qPCR). Additionally, the incidence of MACEs during a 6-month follow-up period after percutaneous coronary intervention (PCI) was collected in the STEMI patient cohort.

Results

Before and after propensity score matching (PSM), Circ_0051386 all had higher expression levels in the patients with STEMI than the normal subjects (all p < .001)and robust diagnosis values for the STEMI (AUC = 0.766, 0.779). Kaplan–Meier curves showed the high expression Circ_0051386 group had a higher occurrence rate of MACEs during a 6-month follow-up after PCI in patients with STEMI and this phenomenon was confirmed by internal validation (all p < .05). In addition, the multivariate COX regression showed gensini score (HR = 1.020, 95% CI = 1.002 − 1.038, p = .028) and Circ_0051386 (HR = 2.468, 95% CI =1.548–3.935, p < .001)were independent risk factors of the occurrence of MACEs in patients with STEMI after PCI. Pearson analysis presented that Circ_0051386 was positively correlated with gensini scores (r = 0.33), IL-1β (r = 0.55)and TNF-α(r = 0.41).

Conclusion

Our study indicated that Circ_0051386 is a biomarker of the diagnostic for STEMI and the predictor of the MACEs in STEMI patients after PCI. Its potential role in STEMI may be the regulation of inflammation in the vascular endothelial.

Keywords:

• Circ_0051386
• acute ST-segment elevation myocardial infarction
• adverse major adverse cardiovascular events

Ethics statement

The standards of the current study were approved by the ethics committee (2018-012-09) of Xiantao first people’s hospital, and all details were based on the declaration of Helsinki.

Patient consent

All the informed consent of patients was obtained.

Disclosure statement

No commercial or financial relationships were established between any of the authors of the current study.

Authors contributions

Xu Jinlin: designed the study and completed the writing.

Wang Zhiwei: data analysis. Ai Yu: completed the drawings and revise the manuscript. Wen Ye: interpreted the results

Data availability statement

The original data can be acquired from the corresponding author.

Additional information

Funding

This work was supported by Health Commission of Hubei Province scientific research project under Grant [WJ2021F099]. We thank GEO project teams for maintaining the data.